{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T12:01:46Z","timestamp":1793793706207,"version":"4.6.1"},"reference-count":100,"publisher":"Bentham Science Publishers Ltd.","issue":"11","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["PPL"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Messenger RNA (mRNA) has gained increasing attention as a valuable tool to cure various\nhuman diseases, particularly malignant tumors. Such growing interest has been triggered largely\nby the phenomenal clinical success of mRNA vaccines developed using lipid nanoparticle (LNP)\ntechnology against COVID-19. mRNA may be used to produce cancer immunotherapies in numerous\ndifferent ways, including cancer vaccines to induce or enhance immunity to tumor-specific\nantigens (TSAs) or tumor-associated antigens (TAAs). mRNA can also be used to adoptively\ntransfer T-cells for the expression of antigen receptors, such as chimeric antigen receptors\n(CARs), therapeutic antibodies, and immunomodulatory proteins to re-engineer the tumor microenvironment.\nHowever, the therapeutic potential of mRNA-based cancer immunotherapy is not\nfully utilized due to a few limitations, such as mRNA instability, production of immunogenicity,\nand a lack of efficient &lt;i&gt;in-vivo&lt;\/i&gt; delivery methods. This review provides an overview of the current\nadvancements and future directions of mRNA-based cancer therapies, including various delivery\nroutes and therapeutic platforms. It addresses the mechanistic basis of mRNA cancer vaccines,\nnon-replicating and self-amplifying mRNA, as well as their clinical development, personalized\nvaccines, and applications of mRNA for encoding antigen receptors, antibodies, and immunomodulatory\nproteins. Moreover, the review addresses nanoparticle-based platforms, such as lipid nanoparticles\n(LNPs), polymeric nanoparticles, and peptide-based nanoparticles, all used to improve\nthe therapeutic effectiveness of mRNA-based drugs by improving their targeted delivery to tissues.\nThis review aims to provide insights into the use of state-of-the-art mRNA-based cancer immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0109298665402963251022054441","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T10:47:06Z","timestamp":1768560426000},"page":"776-790","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["mRNA-Based Cancer Vaccines: A Review of the Current Scenario and Future Prospects"],"prefix":"10.2174","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8958-0077","authenticated-orcid":true,"given":"Sanchari","family":"Bhattacharya","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Guru Nanak Institute of Pharmaceutical Science and Technology, 157\/F, Nilgunj Road,Panihati, Kolkata, 700114, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilufa","family":"Easmin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guru Nanak Institute of Pharmaceutical Science and Technology, 157\/F, Nilgunj Road,Panihati, Kolkata, 700114, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atanu","family":"Panja","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guru Nanak Institute of Pharmaceutical Science and Technology, 157\/F, Nilgunj Road,Panihati, Kolkata, 700114, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3301-1174","authenticated-orcid":true,"given":"Aditi","family":"Nayak","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guru Nanak Institute of Pharmaceutical Science and Technology, 157\/F, Nilgunj Road,Panihati, Kolkata, 700114, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5525-5156","authenticated-orcid":true,"given":"Debjeet","family":"Sur","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guru Nanak Institute of Pharmaceutical Science and Technology, 157\/F, Nilgunj Road,Panihati, Kolkata, 700114, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1029069","DOI":"10.3389\/fimmu.2022.1029069","volume":"13","author":"Vishweshwaraiah Y.L.","year":"2022","unstructured":"Vishweshwaraiah Y.L.; Dokholyan NV; mRNA vaccines for cancer immunotherapy. Front Immu  2022,13,1029069","journal-title":"Front Immu"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1336906","DOI":"10.3389\/fimmu.2024.1336906","volume":"15","author":"Igy\u00e1rt\u00f3 B.Z.","year":"2024","unstructured":"Igy\u00e1rt\u00f3 B.Z.; Qin Z.; The mRNA-LNP vaccines \u2013 the good, the bad and the ugly? Front Immunol  2024,15,1336906","journal-title":"Front Immunol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40290-021-00417-5","volume":"36","author":"Ramachandran S.","year":"2022","unstructured":"Ramachandran S.; Satapathy S.R.; Dutta T.; Delivery strategies for mRNA vaccines. Pharmaceut Med  2022,36(1),11-20","journal-title":"Pharmaceut Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"11256","DOI":"10.3390\/ijms252011256","volume":"25","author":"Malacopol A.T.","year":"2024","unstructured":"Malacopol A.T.; Holst P.J.; Cancer vaccines: Recent insights and future directions. Int J Mol Sci  2024,25(20),11256","journal-title":"Int J Mol Sci"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1002\/wnan.2017","volume":"16","author":"Carvalho H.M.B.","year":"2024","unstructured":"Carvalho H.M.B.; Fidalgo T.A.S.; Ac\u00farcio R.C.; Matos A.I.; Satchi-Fainaro R.; Florindo H.F.; Better, faster, stronger: Accelerating  -Based immunotherapies with nanocarriers. Wiley Interdiscip Rev Nanomed Nanobiotechnol  2024,16(6),2017","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"114416","DOI":"10.1016\/j.addr.2022.114416","volume":"188","author":"Hald A.C.","year":"2022","unstructured":"Hald A.C.; Kulkarni J.A.; Witzigmann D.; Lind M.; Petersson K.; Simonsen J.B.; The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv Drug Deliv Rev  2022,188,114416","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"2303261","DOI":"10.1002\/adma.202303261","volume":"35","author":"Zong Y.","year":"2023","unstructured":"Zong Y.; Lin Y.; Wei T.; Cheng Q.; Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy. Adv Mater  2023,35(51),2303261","journal-title":"Adv Mater"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","volume":"54","author":"Alameh M.G.","year":"2021","unstructured":"Alameh M.G.; Tomb\u00e1cz I.; Bettini E.; Lederer K.; Ndeupen S.; Sittplangkoon C.; Wilmore J.R.; Gaudette B.T.; Soliman O.Y.; Pine M.; Hicks P.; Manzoni T.B.; Knox J.J.; Johnson J.L.; Laczk\u00f3 D.; Muramatsu H.; Davis B.; Meng W.; Rosenfeld A.M.; Strohmeier S.; Lin P.J.C.; Mui B.L.; Tam Y.K.; Karik\u00f3 K.; Jacquet A.; Krammer F.; Bates P.; Cancro M.P.; Weissman D.; Luning Prak E.T.; Allman D.; Igy\u00e1rt\u00f3 B.Z.; Locci M.; Pardi N.; Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity  2021,54(12),2877-2892.e7","journal-title":"Immunity"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1177\/08971900211009650","volume":"35","author":"Teo S.P.","year":"2022","unstructured":"Teo S.P.; Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273. J Pharm Pract  2022,35(6),947-951","journal-title":"J Pharm Pract"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s40588-021-00162-y","volume":"8","author":"Noor R.","year":"2021","unstructured":"Noor R.; Developmental status of the potential vaccines for the mitigation of the covid-19 pandemic and a focus on the effectiveness of the pfizer-biontech and moderna mRNA vaccines. Curr Clin Microbiol Rep  2021,8(3),178-185","journal-title":"Curr Clin Microbiol Rep"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.humimm.2022.08.004","volume":"83","author":"Alesci A.","year":"2022","unstructured":"Alesci A.; Gitto M.; Kota\u0144ska M.; Lo Cascio P.; Miller A.; Nicosia N.; Fumia A.; Pergolizzi S.; Immunogenicity, effectiveness, safety and psychological impact of COVID-19 mRNA vaccines. Hum Immunol  2022,83(11),755-767","journal-title":"Hum Immunol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","volume":"23","author":"Lorentzen C.L.","year":"2022","unstructured":"Lorentzen C.L.; Haanen J.B.; Met \u00d6.; Svane I.M.; Clinical advances and ongoing trials of mRNA vaccines for cancer treatment. Lancet Oncol  2022,23(10),e450-e458","journal-title":"Lancet Oncol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12943-021-01348-0","volume":"20","author":"Beck J.D.","year":"2021","unstructured":"Beck J.D.; Reidenbach D.; Salomon N.; Sahin U.; T\u00fcreci \u00d6.; Vormehr M.; Kranz L.M.; mRNA therapeutics in cancer immunotherapy. Mol Cancer  2021,20(1),69","journal-title":"Mol Cancer"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"6582","DOI":"10.3390\/ijms21186582","volume":"21","author":"Xu S.","year":"2020","unstructured":"Xu S.; Yang K.; Li R.; Zhang L.; mRNA vaccine era\u2014mechanisms, drug platform and clinical prospection. Int J Mol Sci  2020,21(18),6582","journal-title":"Int J Mol Sci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1002\/ctm2.1384","volume":"13","author":"Li Y.","year":"2023","unstructured":"Li Y.; Wang M.; Peng X.; Yang Y.; Chen Q.; Liu J.; She Q.; Tan J.; Lou C.; Liao Z.; Li X.; mRNA vaccine in cancer therapy: Current advance and future outlook. Clin Transl Med  2023,13(8),1384","journal-title":"Clin Transl Med"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12943-021-01311-z","volume":"20","author":"Wang Y.","year":"2021","unstructured":"Wang Y.; Zhang Z.; Luo J.; Han X.; Wei Y.; Wei X.; mRNA vaccine: A potential therapeutic strategy. Mol Cancer  2021,20(1),33","journal-title":"Mol Cancer"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"e00041-24","DOI":"10.1128\/cmr.00041-24","volume":"37","author":"Ahmed S.","year":"2024","unstructured":"Ahmed S.; Herschhorn A.; mRNA-based HIV-1 vaccines. Clin Microbiol Rev  2024,37(3),e00041-24","journal-title":"Clin Microbiol Rev"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1016\/j.ymthe.2022.07.007","volume":"30","author":"Bevers S.","year":"2022","unstructured":"Bevers S.; Kooijmans S.A.A.; Van de Velde E.; Evers M.J.W.; Seghers S.; Gitz-Francois J.J.J.M.; van Kronenburg N.C.H.; Fens M.H.A.M.; Mastrobattista E.; Hassler L.; Sork H.; Lehto T.; Ahmed K.E.; El Andaloussi S.; Fiedler K.; Breckpot K.; Maes M.; Van Hoorick D.; Bastogne T.; Schiffelers R.M.; De Koker S.; mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells. Mol Ther  2022,30(9),3078-3094","journal-title":"Mol Ther"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"103670","DOI":"10.1016\/j.autrev.2024.103670","volume":"23","author":"Pinte L.","year":"2024","unstructured":"Pinte L.; Dima A.; Draghici A.; Caraghiulea M.; Zamfir-Gradinaru I.A.; Baicus C.; Autoimmunity, a relevant exclusion criterion in the development of mRNA-based compounds: A systematic review of clinical trials registries. Autoimmun Rev  2024,23(12),103670","journal-title":"Autoimmun Rev"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3390\/vaccines9020097","volume":"9","author":"Blakney A.K.","year":"2021","unstructured":"Blakney A.K.; Ip S.; Geall A.J.; An update on self-amplifying mRNA vaccine development. Vaccines  2021,9(2),97","journal-title":"Vaccines"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3390\/pathogens12010138","volume":"12","author":"Schmidt C.","year":"2023","unstructured":"Schmidt C.; Schnierle B.S.; Self-amplifying RNA vaccine candidates: Alternative platforms for mRNA vaccine development. Pathogens  2023,12(1),138","journal-title":"Pathogens"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"eabn3464","DOI":"10.1126\/scitranslmed.abn3464","volume":"15","author":"Ramos da Silva J.","year":"2023","unstructured":"Ramos da Silva J.; Bitencourt R.K.; Formoso P.G.; Silva S.N.; Muramatsu H.; de Oliveira S.M.; Porchia B.F.M.M.; Moreno A.C.R.; Aps L.R.M.M.; Venceslau-Carvalho A.A.; Tomb\u00e1cz I.; Fotoran W.L.; Karik\u00f3 K.; Lin P.J.C.; Tam Y.K.; de Oliveira D.M.; Pardi N.; de Souza F.L.C.; Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice. Sci Transl Med  2023,15(686),eabn3464","journal-title":"Sci Transl Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s12033-021-00432-6","volume":"64","author":"Bhattacharya M.","year":"2022","unstructured":"Bhattacharya M.; Sharma A.R.; Ghosh P.; Patra P.; Patra B.C.; Lee S.S.; Chakraborty C.; Bioengineering of novel non-replicating mRNA (NRM) and self-amplifying mRNA (SAM) vaccine candidates against SARS-CoV-2 using immunoinformatics approach. Mol Biotechnol  2022,64(5),510-525","journal-title":"Mol Biotechnol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1208\/s12249-021-02058-y","volume":"22","author":"Khehra N.","year":"2021","unstructured":"Khehra N.; Padda I.; Jaferi U.; Atwal H.; Narain S.; Parmar M.S.; Tozinameran (BNT162b2) vaccine: The journey from preclinical research to clinical trials and authorization. AAPS PharmSciTech  2021,22(5),172","journal-title":"AAPS PharmSciTech"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"103341","DOI":"10.1016\/j.drudis.2022.103341","volume":"27","author":"Pourseif M.M.","year":"2022","unstructured":"Pourseif M.M.; Masoudi-Sobhanzadeh Y.; Azari E.; Parvizpour S.; Barar J.; Ansari R.; Omidi Y.; Self-amplifying mRNA vaccines: Mode of action, design, development and optimization. Drug Discov Today  2022,27(11),103341","journal-title":"Drug Discov Today"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s41571-024-00902-1","volume":"21","author":"Sayour E.J.","year":"2024","unstructured":"Sayour E.J.; Boczkowski D.; Mitchell D.A.; Nair S.K.; Cancer mRNA vaccines: Clinical advances and future opportunities. Nat Rev Clin Oncol  2024,21(7),489-500","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"100562","DOI":"10.1016\/j.medj.2024.11.015","volume":"6","author":"Yaremenko A.V.","year":"2025","unstructured":"Yaremenko A.V.; Khan M.M.; Zhen X.; Tang Y.; Tao W.; Clinical advances of mRNA vaccines for cancer immunotherapy. Med (N Y)  2025,6(1),100562","journal-title":"Med (N Y)"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1016\/j.ymthe.2022.02.016","volume":"30","author":"Szab\u00f3 G.T.","year":"2022","unstructured":"Szab\u00f3 G.T.; Mahiny A.J.; Vlatkovic I.; COVID-19 mRNA vaccines: Platforms and current developments. Mol Ther  2022,30(5),1850-1868","journal-title":"Mol Ther"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.1172\/JCI134915","volume":"130","author":"Cafri G.","year":"2020","unstructured":"Cafri G.; Gartner J.J.; Zaks T.; Hopson K.; Levin N.; Paria B.C.; Parkhurst M.R.; Yossef R.; Lowery F.J.; Jafferji M.S.; Prickett T.D.; Goff S.L.; McGowan C.T.; Seitter S.; Shindorf M.L.; Parikh A.; Chatani P.D.; Robbins P.F.; Rosenberg S.A.; mRNA vaccine\u2013induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J Clin Invest  2020,130(11),5976-5988","journal-title":"J Clin Invest"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1002168","DOI":"10.3389\/fonc.2022.1002168","volume":"12","author":"Di Cosimo S.","year":"2022","unstructured":"Di Cosimo S.; Lupo-Stanghellini M.T.; Costantini M.; Mantegazza R.; Ciceri F.; Salvarani C.; Zinzani P.L.; Mantovani A.; Ciliberto G.; Uccelli A.; Baldanti F.; Apolone G.; Delcuratolo S.; Morrone A.; Locatelli F.; Agrati C.; Silvestris N.; Safety of third dose of COVID-19 vaccination in frail patients: Results from the prospective Italian VAX4FRAIL study. Front Oncol  2022,12,1002168","journal-title":"Front Oncol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1586\/14760584.2014.957684","volume":"14","author":"Benteyn D.","year":"2015","unstructured":"Benteyn D.; Heirman C.; Bonehill A.; Thielemans K.; Breckpot K.; mRNA-based dendritic cell vaccines. Expert Rev Vaccines  2015,14(2),161-176","journal-title":"Expert Rev Vaccines"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/978-1-4939-6481-9_11","volume":"1499","author":"Bialkowski L.","year":"2017","unstructured":"Bialkowski L.; Van der Jeught K.; Renmans D.; van Weijnen A.; Heirman C.; Keyaerts M.; Breckpot K.; Thielemans K.; Adjuvant-enhanced mRNA vaccines. Methods Mol Biol  2017,1499,179-191","journal-title":"Methods Mol Biol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1089\/nat.2021.0103","volume":"32","author":"Gilboa E.","year":"2022","unstructured":"Gilboa E.; Boczkowski D.; Nair S.K.; The Quest for mRNA Vaccines. Nucleic Acid Ther  2022,32(6),449-456","journal-title":"Nucleic Acid Ther"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2400633","DOI":"10.1002\/smtd.202400633","volume":"9","author":"Das R.","year":"2025","unstructured":"Das R.; Ge X.; Fei F.; Parvanian S.; Weissleder R.; Garris C.S.; Lipid nanoparticle-mRNA engineered dendritic cell based adoptive cell therapy enhances cancer immune response. Small Methods  2025,9(1),2400633","journal-title":"Small Methods"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"F1","DOI":"10.1097\/QAD.0b013e32834f33e8","volume":"26","author":"Van Gulck E.","year":"2012","unstructured":"Van Gulck E.; Vlieghe E.; Vekemans M.; Van Tendeloo V.F.I.; Van De Velde A.; Smits E.; Anguille S.; Cools N.; Goossens H.; Mertens L.; De Haes W.; Wong J.; Florence E.; Vanham G.; Berneman Z.N.; mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. AIDS  2012,26(4),F1-F12","journal-title":"AIDS"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"Pardi N.","year":"2018","unstructured":"Pardi N.; Hogan M.J.; Porter F.W.; Weissman D.; mRNA vaccines \u2014 a new era in vaccinology. Nat Rev Drug Discov  2018,17(4),261-279","journal-title":"Nat Rev Drug Discov"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.coi.2020.01.008","volume":"65","author":"Pardi N.","year":"2020","unstructured":"Pardi N.; Hogan M.J.; Weissman D.; Recent advances in mRNA vaccine technology. Curr Opin Immunol  2020,65,14-20","journal-title":"Curr Opin Immunol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"Hou X.","year":"2021","unstructured":"Hou X.; Zaks T.; Langer R.; Dong Y.; Lipid nanoparticles for mRNA delivery. Nat Rev Mater  2021,6(12),1078-1094","journal-title":"Nat Rev Mater"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","volume":"20","author":"Miao L.","year":"2021","unstructured":"Miao L.; Zhang Y.; Huang L.; mRNA vaccine for cancer immunotherapy. Mol Cancer  2021,20(1),41","journal-title":"Mol Cancer"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"122628","DOI":"10.1016\/j.biomaterials.2024.122628","volume":"310","author":"Cao Q.","year":"2024","unstructured":"Cao Q.; Fang H.; Tian H.; mRNA vaccines contribute to innate and adaptive immunity to enhance immune response in vivo. Biomaterials  2024,310,122628","journal-title":"Biomaterials"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"Rojas LA","year":"2023","unstructured":"Rojas LA; Sethna Z; Soares KC; Olcese C; Pang N; Patterson E; Lihm J; Ceglia N; Guasp P; Chu A; Yu R; Chandra AK; Waters T; Ruan J; Amisaki M; Zebboudj A; Odgerel Z; Payne G; Derhovanessian E; M\u00fcller F; Rhee I; Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature  2023,618(7963),144-150","journal-title":"Nature"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20892\/j.issn.2095-3941.2023.0395","volume":"21","author":"Li X.","year":"2023","unstructured":"Li X.; You J.; Hong L.; Liu W.; Guo P.; Hao X.; Neoantigen cancer vaccines: A new star on the horizon. Cancer Biol Med  2023,21(4),1-38","journal-title":"Cancer Biol Med"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1158\/2159-8290.CD-24-1196","volume":"14","author":"Berraondo P.","year":"2024","unstructured":"Berraondo P.; Cuesta R.; Sanmamed M.F.; Melero I.; Immunogenicity and efficacy of personalized adjuvant mRNA cancer vaccines. Cancer Discov  2024,14(11),2021-2024","journal-title":"Cancer Discov"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"100469","DOI":"10.1016\/j.jgeb.2025.100469","volume":"23","author":"Hussain A.","year":"2025","unstructured":"Hussain A.; Fareed A.; Personalized medicine in pancreatic cancer: Harnessing the potential of mRNA vaccines. J Genet Eng Biotechnol  2025,23(1),100469","journal-title":"J Genet Eng Biotechnol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s10238-023-01020-5","volume":"23","author":"Mei Y.","year":"2023","unstructured":"Mei Y.; Wang X.; RNA modification in mRNA cancer vaccines. Clin Exp Med  2023,23(6),1917-1931","journal-title":"Clin Exp Med"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.ymthe.2020.09.038","volume":"29","author":"Shemesh C.S.","year":"2021","unstructured":"Shemesh C.S.; Hsu J.C.; Hosseini I.; Shen B.Q.; Rotte A.; Twomey P.; Girish S.; Wu B.; Personalized cancer vaccines: Clinical landscape, challenges, and opportunities. Mol Ther  2021,29(2),555-570","journal-title":"Mol Ther"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40779-022-00416-w","volume":"9","author":"Huang X.","year":"2022","unstructured":"Huang X.; Zhang G.; Tang T.Y.; Gao X.; Liang T.B.; Personalized pancreatic cancer therapy: From the perspective of mRNA vaccine. Mil Med Res  2022,9(1),53","journal-title":"Mil Med Res"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","volume":"27","author":"Kowalski P.S.","year":"2019","unstructured":"Kowalski P.S.; Rudra A.; Miao L.; Anderson D.G.; Delivering the messenger: Advances in technologies for therapeutic mRNA delivery. Mol Ther  2019,27(4),710-728","journal-title":"Mol Ther"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41587-022-01393-0","volume":"41","author":"Chen R.","year":"2023","unstructured":"Chen R.; Wang S.K.; Belk J.A.; Amaya L.; Li Z.; Cardenas A.; Abe B.T.; Chen C.K.; Wender P.A.; Chang H.Y.; Engineering circular RNA for enhanced protein production. Nat Biotechnol  2023,41(2),262-272","journal-title":"Nat Biotechnol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1021\/acs.accounts.1c00550","volume":"54","author":"Wang C.","year":"2021","unstructured":"Wang C.; Zhang Y.; Dong Y.; Lipid nanoparticle\u2013mRNA formulations for therapeutic applications. Acc Chem Res  2021,54(23),4283-4293","journal-title":"Acc Chem Res"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/s41590-024-01833-w","volume":"25","author":"Schiffner T.","year":"2024","unstructured":"Schiffner T.; Phung I.; Ray R.; Irimia A.; Tian M.; Swanson O.; Lee J.H.; Lee C.C.D.; Marina-Z\u00e1rate E.; Cho S.Y.; Huang J.; Ozorowski G.; Skog P.D.; Serra A.M.; Rantalainen K.; Allen J.D.; Baboo S.; Rodriguez O.L.; Himansu S.; Zhou J.; Hurtado J.; Flynn C.T.; McKenney K.; Havenar-Daughton C.; Saha S.; Shields K.; Schultze S.; Smith M.L.; Liang C.H.; Toy L.; Pecetta S.; Lin Y.C.; Willis J.R.; Sesterhenn F.; Kulp D.W.; Hu X.; Cottrell C.A.; Zhou X.; Ruiz J.; Wang X.; Nair U.; Kirsch K.H.; Cheng H.L.; Davis J.; Kalyuzhniy O.; Liguori A.; Diedrich J.K.; Ngo J.T.; Lewis V.; Phelps N.; Tingle R.D.; Spencer S.; Georgeson E.; Adachi Y.; Kubitz M.; Eskandarzadeh S.; Elsliger M.A.; Amara R.R.; Landais E.; Briney B.; Burton D.R.; Carnathan D.G.; Silvestri G.; Watson C.T.; Yates J.R.; Paulson J.C.; Crispin M.; Grigoryan G.; Ward A.B.; Sok D.; Alt F.W.; Wilson I.A.; Batista F.D.; Crotty S.; Schief W.R.; Vaccination induces broadly neutralizing antibody precursors to HIV gp41. Nat Immunol  2024,25(6),1073-1082","journal-title":"Nat Immunol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1016\/j.immuni.2022.09.001","volume":"55","author":"Willis J.R.","year":"2022","unstructured":"Willis J.R.; Berndsen Z.T.; Ma K.M.; Steichen J.M.; Schiffner T.; Landais E.; Liguori A.; Kalyuzhniy O.; Allen J.D.; Baboo S.; Omorodion O.; Diedrich J.K.; Hu X.; Georgeson E.; Phelps N.; Eskandarzadeh S.; Groschel B.; Kubitz M.; Adachi Y.; Mullin T.M.; Alavi N.B.; Falcone S.; Himansu S.; Carfi A.; Wilson I.A.; Yates J.R.; Paulson J.C.; Crispin M.; Ward A.B.; Schief W.R.; Human immunoglobulin repertoire analysis guides design of vaccine priming immunogens targeting HIV V2-apex broadly neutralizing antibody precursors. Immunity  2022,55(11),2149-2167.e9","journal-title":"Immunity"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.tibtech.2023.08.005","volume":"42","author":"Wu J.","year":"2024","unstructured":"Wu J.; Wu W.; Zhou B.; Li B.; Chimeric antigen receptor therapy meets mRNA technology. Trends Biotechnol  2024,42(2),228-240","journal-title":"Trends Biotechnol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41551-025-01343-6","volume":"9","author":"Wang J.","year":"2025","unstructured":"Wang J.; Zhang Y.; Jia Y.; Xing H.; Xu F.; Xia B.; Lai W.; Yuan Y.; Li X.; Shan S.; Chen J.; Guo W.; Zhang J.; Zheng A.; Li J.; Gong N.; Liang X.J.; Targeting vaccines to dendritic cells by mimicking the processing and presentation of antigens in xenotransplant rejection. Nat Biomed Eng  2025,9(2),201-214","journal-title":"Nat Biomed Eng"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.ymthe.2021.03.002","volume":"29","author":"Tse S.W.","year":"2021","unstructured":"Tse S.W.; McKinney K.; Walker W.; Nguyen M.; Iacovelli J.; Small C.; Hopson K.; Zaks T.; Huang E.; mRNA-encoded, constitutively active STING is a potent genetic adjuvant of antigen-specific CD8 T cell response. Mol Ther  2021,29(7),2227-2238","journal-title":"Mol Ther"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.ymthe.2019.05.012","volume":"27","author":"Rybakova Y.","year":"2019","unstructured":"Rybakova Y.; Kowalski P.S.; Huang Y.; Gonzalez J.T.; Heartlein M.W.; DeRosa F.; Delcassian D.; Anderson D.G.; mRNA delivery for therapeutic anti-her2 antibody expression in vivo. Mol Ther  2019,27(8),1415-1423","journal-title":"Mol Ther"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"7375","DOI":"10.1016\/j.vaccine.2021.10.068","volume":"39","author":"Wagner A.","year":"2021","unstructured":"Wagner A.; Jasinska J.; Tomosel E.; Zielinski C.C.; Wiedermann U.; Absent antibody production following COVID19 vaccination with mRNA in patients under immunosuppressive treatments. Vaccine  2021,39(51),7375-7378","journal-title":"Vaccine"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2302\/kjm.71-001-ABST","volume":"71","author":"Karik\u00f3 K.","year":"2022","unstructured":"Karik\u00f3 K.; Developing mRNA for therapy. Keio J Med  2022,71(1),31","journal-title":"Keio J Med"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"2313226","DOI":"10.1002\/adma.202313226","volume":"36","author":"Metzloff A.E.","year":"2024","unstructured":"Metzloff A.E.; Padilla M.S.; Gong N.; Billingsley M.M.; Han X.; Merolle M.; Mai D.; Figueroa-Espada C.G.; Thatte A.S.; Haley R.M.; Mukalel A.J.; Hamilton A.G.; Alameh M.G.; Weissman D.; Sheppard N.C.; June C.H.; Mitchell M.J.; Antigen presenting cell mimetic lipid nanoparticles for rapid mRNA car T cell cancer immunotherapy. Adv Mater  2024,36(26),2313226","journal-title":"Adv Mater"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"2418306122","DOI":"10.1073\/pnas.2418306122","volume":"122","author":"Zhu Q.","year":"2025","unstructured":"Zhu Q.; Yu C.; Chen Y.; Luo W.; Li M.; Zou J.; Xiao F.; An S.; Saiding Q.; Tao W.; Kong N.; Xie T.; Dual mRNA nanoparticles strategy for enhanced pancreatic cancer treatment and \u03b2-elemene combination therapy. Proc Natl Acad Sci USA  2025,122(11),2418306122","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1021\/acs.biomac.1c00476","volume":"22","author":"Jatczak-Pawlik I.","year":"2021","unstructured":"Jatczak-Pawlik I.; Gorzkiewicz M.; Studzian M.; Zinke R.; Appelhans D.; Klajnert-Maculewicz B.; Pu\u0142aski \u0141.; Nanoparticles for directed immunomodulation: Mannose-functionalized glycodendrimers induce interleukin-8 in myeloid cell lines. Biomacromolecules  2021,22(8),3396-3407","journal-title":"Biomacromolecules"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"122185","DOI":"10.1016\/j.biomaterials.2023.122185","volume":"300","author":"Neshat S.Y.","year":"2023","unstructured":"Neshat S.Y.; Chan C.H.R.; Harris J.; Zmily O.M.; Est-Witte S.; Karlsson J.; Shannon S.R.; Jain M.; Doloff J.C.; Green J.J.; Tzeng S.Y.; Polymeric nanoparticle gel for intracellular mRNA delivery and immunological reprogramming of tumors. Biomaterials  2023,300,122185","journal-title":"Biomaterials"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"126017","DOI":"10.1016\/j.ijbiomac.2023.126017","volume":"249","author":"Zhang S.","year":"2023","unstructured":"Zhang S.; Zhang Q.; Li C.; Xing N.; Zhou P.; Jiao Y.; A zinc-modified Anemarrhena asphodeloides polysaccharide complex enhances immune activity via the NF-\u03baB and MAPK signaling pathways. Int J Biol Macromol  2023,249,126017","journal-title":"Int J Biol Macromol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1002\/med.22016","volume":"44","author":"Tian X.","year":"2024","unstructured":"Tian X.; Ai J.; Tian X.; Wei X.; cGAS-STING pathway agonists are promising vaccine adjuvants. Med Res Rev  2024,44(4),1768-1799","journal-title":"Med Res Rev"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.3390\/molecules29133121","volume":"29","author":"Yu X.","year":"2024","unstructured":"Yu X.; Cai L.; Yao J.; Li C.; Wang X.; Agonists and inhibitors of the cGAS-STING pathway. Molecules  2024,29(13),3121","journal-title":"Molecules"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"2300275","DOI":"10.1002\/mabi.202300275","volume":"23","author":"Chen P.","year":"2023","unstructured":"Chen P.; Paraiso W.K.D.; Cabral H.; Revitalizing cytokine-based cancer immunotherapy through advanced delivery systems. Macromol Biosci  2023,23(12),2300275","journal-title":"Macromol Biosci"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/17425247.2023.2208344","volume":"20","author":"Bohmer M.","year":"2023","unstructured":"Bohmer M.; Xue Y.; Jankovic K.; Dong Y.; Advances in engineering and delivery strategies for cytokine immunotherapy. Expert Opin Drug Deliv  2023,20(5),579-595","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/bs.ircmb.2022.05.002","volume":"369","author":"Di Trani C.A.","year":"2022","unstructured":"Di Trani C.A.; Cirella A.; Arrizabalaga L.; Fernandez-Sendin M.; Bella A.; Aranda F.; Melero I.; Berraondo P.; Overcoming the limitations of cytokines to improve cancer therapy. Int Rev Cell Mol Biol  2022,369,107-141","journal-title":"Int Rev Cell Mol Biol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1592795","DOI":"10.3389\/fimmu.2025.1592795","volume":"16","author":"Wang R.","year":"2025","unstructured":"Wang R.; Kubiatowicz L.J.; Zhang R.; Bao L.; Fang R.H.; Zhang L.; Nanoparticle approaches for manipulating cytokine delivery and neutralization. Front Immunol  2025,16,1592795","journal-title":"Front Immunol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41565-023-01580-3","volume":"19","author":"Liu M.","year":"2024","unstructured":"Liu M.; Hu S.; Yan N.; Popowski K.D.; Cheng K.; Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity. Nat Nanotechnol  2024,19(4),565-575","journal-title":"Nat Nanotechnol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0021-9258(17)49904-2","volume":"295","author":"Mariuzza R.A.","year":"2020","unstructured":"Mariuzza R.A.; Agnihotri P.; Orban J.; The structural basis of T-cell receptor (TCR) activation: An enduring enigma. J Biol Chem  2020,295(4),914-925","journal-title":"J Biol Chem"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coi.2021.07.006","volume":"74","author":"Joshi K.","year":"2022","unstructured":"Joshi K.; Milighetti M.; Chain B.M.; Application of T cell receptor (TCR) repertoire analysis for the advancement of cancer immunotherapy. Curr Opin Immunol  2022,74,1-8","journal-title":"Curr Opin Immunol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.apsb.2019.08.010","volume":"10","author":"Fu Y.","year":"2020","unstructured":"Fu Y.; Lin Q.; Zhang Z.; Zhang L.; Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity. Acta Pharm Sin B  2020,10(3),414-433","journal-title":"Acta Pharm Sin B"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"719116","DOI":"10.3389\/fimmu.2021.719116","volume":"12","author":"Warwas K.M.","year":"2021","unstructured":"Warwas K.M.; Meyer M.; Gon\u00e7alves M.; Moldenhauer G.; Bulbuc N.; Knabe S.; Luckner-Minden C.; Ziegelmeier C.; Heussel C.P.; Z\u00f6rnig I.; J\u00e4ger D.; Momburg F.; Co-stimulatory bispecific antibodies induce enhanced T cell activation and tumor cell killing in breast cancer models. Front Immunol  2021,12,719116","journal-title":"Front Immunol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/cbin.10729","volume":"41","author":"Cacan E.","year":"2017","unstructured":"Cacan E.; Epigenetic-mediated immune suppression of positive co-stimulatory molecules in chemoresistant ovarian cancer cells. Cell Biol Int  2017,41(3),328-339","journal-title":"Cell Biol Int"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12951-022-01478-7","volume":"20","author":"Kiaie S.H.","year":"2022","unstructured":"Kiaie S.H.; Majidi Zolbanin N.; Ahmadi A.; Bagherifar R.; Valizadeh H.; Kashanchi F.; Jafari R.; Recent advances in mRNA-LNP therapeutics: Immunological and pharmacological aspects. J Nanobiotechnology  2022,20(1),276","journal-title":"J Nanobiotechnology"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.3390\/pharmaceutics14122682","volume":"14","author":"Yang L.","year":"2022","unstructured":"Yang L.; Gong L.; Wang P.; Zhao X.; Zhao F.; Zhang Z.; Li Y.; Huang W.; Recent advances in lipid nanoparticles for delivery of mRNA. Pharmaceutics  2022,14(12),2682","journal-title":"Pharmaceutics"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"Sahin U.","year":"2014","unstructured":"Sahin U.; Karik\u00f3 K.; T\u00fcreci \u00d6.; mRNA-based therapeutics \u2014 developing a new class of drugs. Nat Rev Drug Discov  2014,13(10),759-780","journal-title":"Nat Rev Drug Discov"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"12181","DOI":"10.1021\/acs.chemrev.1c00244","volume":"121","author":"Zhang Y.","year":"2021","unstructured":"Zhang Y.; Sun C.; Wang C.; Jankovic K.E.; Dong Y.; Lipids and lipid derivatives for rna delivery. Chem Rev  2021,121(20),12181-12277","journal-title":"Chem Rev"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"738","DOI":"10.7150\/thno.84291","volume":"14","author":"Li X.","year":"2024","unstructured":"Li X.; Qi J.; Wang J.; Hu W.; Zhou W.; Wang Y.; Li T.; Nanoparticle technology for mRNA: Delivery strategy, clinical application and developmental landscape. Theranostics  2024,14(2),738-760","journal-title":"Theranostics"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.3390\/pharmaceutics15041127","volume":"15","author":"Hajiaghapour A.M.","year":"2023","unstructured":"Hajiaghapour A.M.; Dayani F.; Saedi S.F.; Kamedi A.; Neill A.O.; MacLoughlin R.; Doroudian M.; Lipid nanoparticles as promising carriers for mRNA vaccines for viral lung infections. Pharmaceutics  2023,15(4),1127","journal-title":"Pharmaceutics"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"10166","DOI":"10.3390\/ijms251810166","volume":"25","author":"Liu Y.","year":"2024","unstructured":"Liu Y.; Huang Y.; He G.; Guo C.; Dong J.; Wu L.; Development of mRNA lipid nanoparticles: Targeting and therapeutic aspects. Int J Mol Sci  2024,25(18),10166","journal-title":"Int J Mol Sci"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","volume":"15","author":"Tenchov R.","year":"2021","unstructured":"Tenchov R.; Bird R.; Curtze A.E.; Zhou Q.; Lipid nanoparticles\u2500from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano  2021,15(11),16982-17015","journal-title":"ACS Nano"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.3390\/pharmaceutics14112520","volume":"14","author":"Kalita T.","year":"2022","unstructured":"Kalita T.; Dezfouli S.A.; Pandey L.M.; Uludag H.; siRNA functionalized lipid nanoparticles (LNPs) in management of diseases. Pharmaceutics  2022,14(11),2520","journal-title":"Pharmaceutics"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"115461","DOI":"10.1016\/j.addr.2024.115461","volume":"215","author":"Bader J.","year":"2024","unstructured":"Bader J.; Brigger F.; Leroux J.C.; Extracellular vesicles versus lipid nanoparticles for the delivery of nucleic acids. Adv Drug Deliv Rev  2024,215,115461","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3390\/pharmaceutics16060771","volume":"16","author":"Gambaro R.","year":"2024","unstructured":"Gambaro R.; Rivero B.I.; Limeres M.J.; Huck-Iriart C.; Svensson M.; Fraude S.; Pretsch L.; Si S.; Lieberwirth I.; Gehring S.; Cacicedo M.; Islan G.A.; Optimizing mRNA-loaded lipid nanoparticles as a potential tool for protein-replacement therapy. Pharmaceutics  2024,16(6),771","journal-title":"Pharmaceutics"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/978-1-0716-2879-9_12","volume":"2606","author":"Yang D.","year":"2023","unstructured":"Yang D.; Song C.Q.; The delivery of ABE mRNA to the adult murine liver by lipid nanoparticles (LNPs). Methods Mol Biol  2023,2606,159-170","journal-title":"Methods Mol Biol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s13346-023-01402-y","volume":"14","author":"Sarode A.","year":"2024","unstructured":"Sarode A.; Patel P.; Vargas-Montoya N.; Allawzi A.; Zhilin-Roth A.; Karmakar S.; Boeglin L.; Deng H.; Karve S.; DeRosa F.; Inhalable dry powder product (DPP) of mRNA lipid nanoparticles (LNPs) for pulmonary delivery. Drug Deliv Transl Res  2024,14(2),360-372","journal-title":"Drug Deliv Transl Res"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1186\/s12951-024-02812-x","volume":"22","author":"Kong W.","year":"2024","unstructured":"Kong W.; Wei Y.; Dong Z.; Liu W.; Zhao J.; Huang Y.; Yang J.; Wu W.; He H.; Qi J.; Role of size, surface charge, and PEGylated lipids of lipid nanoparticles (LNPs) on intramuscular delivery of mRNA. J Nanobiotechnology  2024,22(1),553","journal-title":"J Nanobiotechnology"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","volume":"55","author":"Eygeris Y.","year":"2022","unstructured":"Eygeris Y.; Gupta M.; Kim J.; Sahay G.; Chemistry of lipid nanoparticles for RNA delivery. Acc Chem Res  2022,55(1),2-12","journal-title":"Acc Chem Res"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1554496","DOI":"10.3389\/fimmu.2025.1554496","volume":"16","author":"Lang S.","year":"2025","unstructured":"Lang S.; Zhu Y.; Tan Z.; Zhang Y.; Liang R.; Ren J.; Li P.; Pan F.; Cai L.; Chen Y.H.; Cancer immunotherapy by silencing transcription factor c-Rel using peptide-based nanoparticles. Front Immunol  2025,16,1554496","journal-title":"Front Immunol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"114001","DOI":"10.1016\/j.jconrel.2025.114001","volume":"385","author":"Liu Z.","year":"2025","unstructured":"Liu Z.; Wang X.; Zhu X.; Zhang T.; He Z.; Wu Z.; Liu M.; Li K.; Wei Y.; Liu H.; Lu J.; Lu Q.; Zhu P.; Wang Y.; Chen Z.; Enhancing antigen presentation in cancer stem cells via peptide-based nanoparticles for effective immunotherapy. J Control Release  2025,385,114001","journal-title":"J Control Release"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"115190","DOI":"10.1016\/j.addr.2024.115190","volume":"206","author":"Estap\u00e9 S.M.","year":"2024","unstructured":"Estap\u00e9 S.M.; Garc\u00eda del Valle L.; Schiffelers R.M.; mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond. Adv Drug Deliv Rev  2024,206,115190","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1021\/acsabm.8b00811","volume":"2","author":"Liu Y.","year":"2019","unstructured":"Liu Y.; Yao L.; Cao W.; Liu Y.; Zhai W.; Wu Y.; Wang B.; Gou S.; Qin Y.; Qi Y.; Chen Z.; Gao Y.; Dendritic cell targeting peptide-based nanovaccines for enhanced cancer immunotherapy. ACS Appl Bio Mater  2019,2(3),1241-1254","journal-title":"ACS Appl Bio Mater"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1080\/10717544.2022.2086941","volume":"29","author":"Wang Q.","year":"2022","unstructured":"Wang Q.; Dong Z.; Lou F.; Yin Y.; Zhang J.; Wen H.; Lu T.; Wang Y.; Phenylboronic ester-modified polymeric nanoparticles for promoting TRP2 peptide antigen delivery in cancer immunotherapy. Drug Deliv  2022,29(1),2029-2043","journal-title":"Drug Deliv"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.actbio.2024.12.051","volume":"193","author":"Zhao Z.","year":"2025","unstructured":"Zhao Z.; Fetse J.; Mamani U.F.; Guo Y.; Li Y.; Patel P.; Liu Y.; Lin C.Y.; Li Y.; Mustafa B.; Cheng K.; Development of a peptide-based tumor-activated checkpoint inhibitor for cancer immunotherapy. Acta Biomater  2025,193,484-497","journal-title":"Acta Biomater"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"Weber J.S.","year":"2024","unstructured":"Weber J.S.; Carlino M.S.; Khattak A.; Meniawy T.; Ansstas G.; Taylor M.H.; Kim K.B.; McKean M.; Long G.V.; Sullivan R.J.; Faries M.; Tran T.T.; Cowey C.L.; Pecora A.; Shaheen M.; Segar J.; Medina T.; Atkinson V.; Gibney G.T.; Luke J.J.; Thomas S.; Buchbinder E.I.; Healy J.A.; Huang M.; Morrissey M.; Feldman I.; Sehgal V.; Robert-Tissot C.; Hou P.; Zhu L.; Brown M.; Aanur P.; Meehan R.S.; Zaks T.; Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): A randomised, phase 2b study. Lancet  2024,403(10427),632-644","journal-title":"Lancet"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41587-021-00994-5","volume":"39","author":"Xiao W.","year":"2021","unstructured":"Xiao W.; Ren L.; Chen Z.; Fang L.T.; Zhao Y.; Lack J.; Guan M.; Zhu B.; Jaeger E.; Kerrigan L.; Blomquist T.M.; Hung T.; Sultan M.; Idler K.; Lu C.; Scherer A.; Kusko R.; Moos M.; Xiao C.; Sherry S.T.; Abaan O.D.; Chen W.; Chen X.; Nordlund J.; Liljedahl U.; Maestro R.; Polano M.; Drabek J.; Vojta P.; K\u00f5ks S.; Reimann E.; Madala B.S.; Mercer T.; Miller C.; Jacob H.; Truong T.; Moshrefi A.; Natarajan A.; Granat A.; Schroth G.P.; Kalamegham R.; Peters E.; Petitjean V.; Walton A.; Shen T.W.; Talsania K.; Vera C.J.; Langenbach K.; de Mars M.; Hipp J.A.; Willey J.C.; Wang J.; Shetty J.; Kriga Y.; Raziuddin A.; Tran B.; Zheng Y.; Yu Y.; Cam M.; Jailwala P.; Nguyen C.; Meerzaman D.; Chen Q.; Yan C.; Ernest B.; Mehra U.; Jensen R.V.; Jones W.; Li J.L.; Papas B.N.; Pirooznia M.; Chen Y.C.; Seifuddin F.; Li Z.; Liu X.; Resch W.; Wang J.; Wu L.; Yavas G.; Miles C.; Ning B.; Tong W.; Mason C.E.; Donaldson E.; Lababidi S.; Staudt L.M.; Tezak Z.; Hong H.; Wang C.; Shi L.; Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing. Nat Biotechnol  2021,39(9),1141-1150","journal-title":"Nat Biotechnol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41541-025-01097-x","volume":"10","author":"Gong Z.","year":"2025","unstructured":"Gong Z.; Hu W.; Zhou C.; Guo J.; Yang L.; Wang B.; Recent advances and perspectives on the development of circular RNA cancer vaccines. NPJ Vaccines  2025,10(1),41","journal-title":"NPJ Vaccines"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.7150\/thno.104698","volume":"15","author":"Yu H.","year":"2025","unstructured":"Yu H.; Wen Y.; Yu W.; Lu L.; Yang Y.; Liu C.; Hu Z.; Fang Z.; Huang S.; Optimized circular RNA vaccines for superior cancer immunotherapy. Theranostics  2025,15(4),1420-1438","journal-title":"Theranostics"}],"container-title":["Protein &amp; Peptide Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298665402963251022054441","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/249265\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298665402963251022054441","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T09:01:24Z","timestamp":1773219684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/249265\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":100,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0109298665402963251022054441","relation":{},"ISSN":["0929-8665"],"issn-type":[{"value":"0929-8665","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-03-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}